Literature DB >> 1766477

Presence of a phosphoramidon-sensitive endothelin-converting enzyme which converts big-endothelin-1, but not big-endothelin-3, in the rat vas deferens.

S Télémaque1, P D'Orléans-Juste.   

Abstract

Endothelin-1 (ET-1) enhanced field stimulation-evoked (0.1 Hz), nerve-mediated contractions of the prostatic portion of the rat vas deferens. The human precursor of ET-1, big-endothelin (1-38) (big-ET-1) was only two-fold less potent than ET-1 (pD2 values: 7.30 and 7.49, respectively). The threshold concentrations necessary to elicit an increase of the response to electrical stimulation was lower for ET-1 (5 nmol/l) than for big-ET-1 (25 nmol/l). Endothelin-3 (ET-3) also markedly enhanced the response of the tissue to field stimulation with a potency similar to ET-1 (pD2 value: 7.59). In contrast, the precursor of ET-3, big-endothelin (1-41) (big-ET-3), was inactive at concentrations up to 0.5 mumol/l. Treatment of the preparations with phosphoramidon (50 mumol/l) markedly reduced the twitch enhancement by big-ET-1 without affecting the response to ET-1. Our results suggest the presence of a specific phosphoramidon-sensitive endothelin-converting enzyme which converts big-ET-1 to ET-1 in the rat vas deferens.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1766477     DOI: 10.1007/bf00172593

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  17 in total

1.  Intravascular big endothelin increases circulating levels of endothelin-1 and prostanoids in the rabbit.

Authors:  P D'Orléans-Juste; P S Lidbury; T D Warner; J R Vane
Journal:  Biochem Pharmacol       Date:  1990-05-01       Impact factor: 5.858

2.  Effects of endothelins on nerve-mediated contractions of the mouse vas deferens.

Authors:  G A Rae; J B Calixto
Journal:  Life Sci       Date:  1990       Impact factor: 5.037

3.  Human big endothelin releases prostacyclin in vivo and in vitro through a phosphoramidon-sensitive conversion to endothelin-1.

Authors:  P D'Orléans-Juste; P S Lidbury; S Telemaque; T D Warner; J R Vane
Journal:  J Cardiovasc Pharmacol       Date:  1991       Impact factor: 3.105

4.  Cloning and expression of a cDNA encoding an endothelin receptor.

Authors:  H Arai; S Hori; I Aramori; H Ohkubo; S Nakanishi
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

5.  Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide.

Authors:  M Yanagisawa; A Inoue; T Ishikawa; Y Kasuya; S Kimura; S Kumagaye; K Nakajima; T X Watanabe; S Sakakibara; K Goto
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

6.  Characterization of pre- and postjunctional receptors for neurokinins and kinins in the rat vas deferens.

Authors:  C Tousignant; S Dion; G Drapeau; D Regoli
Journal:  Neuropeptides       Date:  1987 May-Jun       Impact factor: 3.286

7.  Phosphoramidon, a metalloproteinase inhibitor, suppresses the hypertensive effect of big endothelin-1.

Authors:  Y Matsumura; K Hisaki; M Takaoka; S Morimoto
Journal:  Eur J Pharmacol       Date:  1990-08-21       Impact factor: 4.432

8.  cDNA cloning and chromosomal assignment of the gene encoding endothelin 3.

Authors:  K D Bloch; R L Eddy; T B Shows; T Quertermous
Journal:  J Biol Chem       Date:  1989-10-25       Impact factor: 5.157

9.  Different pharmacological profiles of big-endothelin-3 and big-endothelin-1 in vivo and in vitro.

Authors:  P D'Orléans-Juste; S Télémaque; A Claing
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

10.  The activity of peptides of the endothelin family in various mammalian smooth muscle preparations.

Authors:  C A Maggi; S Giuliani; R Patacchini; P Rovero; A Giachetti; A Meli
Journal:  Eur J Pharmacol       Date:  1989-12-12       Impact factor: 4.432

View more
  11 in total

Review 1.  Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer.

Authors:  Lowell Ling; Janet J Maguire; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

2.  Comparison of the cardiovascular and neural activity of endothelin-1, -2, -3 and respective proendothelins: effects of phosphoramidon and thiorphan.

Authors:  G G Mattera; A Eglezos; A R Renzetti; J Mizrahi
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

3.  Differential effects of BQ-123 against endothelin-1 and endothelin-3 on the rat vas deferens: evidence for an atypical endothelin receptor.

Authors:  A Eglezos; P Cucchi; R Patacchini; L Quartara; C A Maggi; J Mizrahi
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

4.  Regional differences in endothelin converting enzyme activity in rat brain: inhibition by phosphoramidon and EDTA.

Authors:  T D Warner; G P Budzik; T Matsumoto; J A Mitchell; U Förstermann; F Murad
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

5.  Inhibition by phosphoramidon of the regional haemodynamic effects of proendothelin-2 and -3 in conscious rats.

Authors:  S M Gardiner; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

6.  Endothelins induce prostacyclin release in both vascular and non-vascular tissue.

Authors:  G G Mattera; R M Catalioto; M Criscuoli; A Subissi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-10       Impact factor: 3.000

7.  Contractile activity of endothelin precursors in the isolated gallbladder of the guinea-pig: presence of an endothelin-converting enzyme.

Authors:  B Battistini; M Woods; L J O'Donnell; T D Warner; R Corder; A Fournier; M J Farthing; J R Vane
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

8.  Characterization of endothelin receptors mediating the effects of the endothelin/sarafotoxin peptides on autonomic neurotransmission in the rat vas deferens and guinea-pig ileum.

Authors:  T D Warner; G H Allcock; E J Mickley; J R Vane
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

Review 9.  Endothelin.

Authors:  Anthony P Davenport; Kelly A Hyndman; Neeraj Dhaun; Christopher Southan; Donald E Kohan; Jennifer S Pollock; David M Pollock; David J Webb; Janet J Maguire
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

10.  Physiological and pharmacological aspects of the vas deferens-an update.

Authors:  David S Koslov; Karl-Erik Andersson
Journal:  Front Pharmacol       Date:  2013-08-22       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.